First test: how does a damaged liver handle this new drug?
NCT ID NCT07018492
Summary
This early-stage study aimed to understand how a drug called BPN14770 behaves in people with different levels of liver damage. Researchers gave a single dose to 32 people, including healthy volunteers and those with mild, moderate, or severe liver impairment. They measured how much of the drug got into the blood and checked for side effects to see if dosing needs adjustment for people with liver problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Division of Clinical Pharmacology, University of Miami
Miami, Florida, 33136, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
-
Texas Liver Institute
San Antonio, Texas, 78215, United States
Conditions
Explore the condition pages connected to this study.